Mallinckrodt 4th-qtr sales and earnings beat analysts’ expectations
US drugmaker Mallinckrodt (NYSE:MNK) has reported a strong set of financial results for the fourth-quarter and full year ended September 26, 2014, which beat analysts’ expectations. Full year net sales increased 15.2% to $2.54 billion, with adjusted diluted earnings per share leaping 57.8% to $4.94, the company stated,
Net sales for the fourth quarter were $789.3 million compared with $545.2 million reported in the fourth quarter of fiscal 2013, an increase of 44.8%, beating Wall Street estimates by $31 million. Strong net sales were driven by the inclusion and performance of HP Acthar Gel (Acthar) repository corticotropin injection and Ofirmev (acetaminophen) injection, acquired in August 2014 and March 2014, respectively, and continuing strength in its base Specialty Controlled Substance Generics portfolio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze